Evidence map›Paper›PMID 35260041›Full record

ArticlePharmaceutical biology2022

Epigallocatechin-3-

Dong Yang, Guanghua Cao, Xiaorong Ba, Haibo Jiang

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutical biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Pro-Inflammatory Signalling PRRopels Cisplatin-Induced Toxicity.International journal of molecular sciences · 2022
    Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Dong YangDepartment of Orthopaedics, Liyang Peoples' Hospital, Changzhou, PR China.
Guanghua CaoDepartment of Orthopaedics, Liyang Peoples' Hospital, Changzhou, PR China.
Xiaorong BaDepartment of Orthopaedics, Liyang Peoples' Hospital, Changzhou, PR China.
Haibo JiangDepartment of Orthopaedics, Liyang Peoples' Hospital, Changzhou, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextEpigallocatechin-3-

objectiveTo explore the roles of EGCG and miR-29b-3p in interleukin-1β (IL-1β)-stimulated chondrocytes. MATERIALS AND

methodsHE and Safranin O staining were used to detect the pathological changes of cartilage tissue in OA patients and healthy people. OA-like chondrocyte injury was mimicked by 5 ng/mL IL-1β stimulation for 24 h

resultsMiR-29b-3p level was upregulated in cartilage tissues of OA patients (3.5-fold change, DISCUSSION AND

conclusionsEGCG is a potential candidate for the treatment of OA, which also can be explored in a novel therapeutic method for other degenerative or inflammatory disorders.

Indexed as

AdultAgedApoptosisCase-Control StudiesCatechinCell LineChondrocytesDose-Response Relationship, DrugExtracellular MatrixHumansInflammationInterleukin-1betaMicroRNAsMiddle AgedOsteoarthritisPTEN PhosphohydrolaseCatechinepigallocatechin gallateInterleukin-1betaMicroRNAsMIRN29B1 microRNA, humanPTEN PhosphohydrolasePTEN protein, humanEpigallocatechin-3-O-gallatemiR-29b-3posteoarthritis (OA)

Identifiers

PMID35260041
PMCPMC8920401
OpenAlexW4221017554

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.